<div id="readability-page-1">Cybin Inc. (OTCMKTS:CLXPF - Get Free Report)'s share price shot up 5.7% on Friday . The company traded as high as $6.00 and last traded at $5.95. 644,862 shares were traded  during mid-day trading, an increase of 17% from the average session volume of 551,962 shares. The stock had previously closed at $5.63.<h2>Cybin Stock Up 5.7%</h2><p>The stock has a market capitalization of $884.16 million and a P/E ratio of -42.50. The business's 50 day simple moving average is $6.17 and its two-hundred day simple moving average is $7.01.</p><h2>Cybin Company Profile</h2> (Get Free Report)<p>Cybin Inc, a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Cybin</li><li>What Investors Need to Know to Beat the Market</li><li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li><li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li><li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li><li>Dividend Capture Strategy: What You Need to Know</li><li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cybin Right Now?</h2><p>Before you consider Cybin, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.</p><p>While Cybin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CYBN

<p>Cybin Inc.'s share price rose 5.7% to $5.95, with trading volume up 17% from average. The company focuses on psychedelic therapeutics. Despite the rise, analysts suggest better stock options than Cybin, which holds a 'Hold' rating.</p>

Cybin (OTCMKTS:CLXPF) Shares Up 5.7% - Time to Buy?